SCHEDULE: Armistice Capital Discloses Virax Biolabs Stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in Virax Biolabs Group Limited ordinary shares.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited.
• This holding represents 4.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The filing date for this amendment is March 31, 2026, with the statement signed on May 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not inherently signal positive or negative performance for the company.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed their significant stake, providing transparency to the market regarding ownership.
• The ownership level of 4.99% is just below the 5% threshold that would trigger more stringent reporting requirements under Schedule 13D.

Negatives

• The filing does not contain any negative financial or operational information about Virax Biolabs Group Limited itself, as it is a disclosure of ownership by an external entity.

Risks

• Potential for increased scrutiny or activism from Armistice Capital, LLC given their significant stake.
• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which could introduce complexities in understanding ultimate control.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Virax Biolabs Group Limited.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's interest in Virax Biolabs Group Limited, a move that could precede further investment or strategic engagement.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Management of Virax Biolabs Group Limited: May need to engage with Armistice Capital, LLC regarding their investment strategy and intentions.
• Competitors: Awareness of a significant institutional investor's interest in the company.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold and manage their investment in Virax Biolabs Group Limited.
• Further amendments to this Schedule 13G will be filed if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Virax Biolabs Group Limited, Armistice Capital, Steven Boyd, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment Management